Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748434 | 1.00 | DPP4 (0.49) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4778870 | 0.97 | DPP4 (0.48) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL1748778 | 0.97 | DPP4 (0.48) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL5129579 | 0.97 | DPP4 (0.48) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL4778879 | 0.97 | DPP4 (0.48) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL1748779 | 0.97 | DPP4 (0.48) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL1748676 | 0.90 | DPP4 (0.49) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL1748677 | 0.90 | DPP4 (0.49) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL2898426 | 0.90 | DPP4 (0.40) | DPP4HDAC8HDAC1HDAC3HDAC2 | |
| SCHEMBL2898430 | 0.90 | DPP4 (0.40) | DPP4HDAC8HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | claimed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | claimed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | claimed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7399878-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-07-15 | — | — | US | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008017852-A1 | DIAMINE-CONTAINING, TETRA- SUBSTITUTED PIPERAZINE COMPOUNDS AS MELANOCORTIN RECEPTOR MODULATORS | PALATIN TECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | NPY1R, MC5R, MC4R | DPP4 1448/4885HDAC8 3368/4885HDAC1 2267/4885 |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | MC4R, MC1R, MC5R | DPP4 820/4885HDAC8 3830/4885HDAC1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.